You were told about the nausea. Maybe your prescriber mentioned it, maybe TikTok did. Either way, nausea on GLP-1 medications has entered the public conversation. Constipation, on the other hand, tends to show up unannounced. It is reported by 16-24% of participants in major clinical trials of semaglutide and tirzepatide, but in real-world practice, the numbers are likely higher. And unlike nausea, which usually improves within weeks, constipation on GLP-1s can persist for the entire duration of treatment if it is not actively managed. The good news: you almost never need to stop your medication because of constipation. There is a clear, stepwise approach that works for most people. But it helps to understand why it is happening in the first place.
Why Do GLP-1 Medications Cause Constipation?
Two mechanisms work together. The first is delayed gastric emptying, which is a core pharmacological effect of GLP-1 receptor agonists. When the stomach empties more slowly, the downstream delivery of material to the small intestine and colon also slows. Reduced peristaltic activity and suppression of the migrating motor complex (MMC) compound this effect. The entire GI tract operates at a lower speed.
The second mechanism is reduced food intake. GLP-1 medications work partly by decreasing appetite and caloric consumption. In STEP 1, participants on semaglutide 2.4 mg reduced their caloric intake by approximately 35% on average. Less food means less residue in the colon, which means less bulk to stimulate peristalsis. The colon relies on mechanical stretch from stool mass as a primary trigger for coordinated contractions. When there is less material, the colon has less reason to contract.
On top of both of these, slower colonic transit gives the colon more time to absorb water from stool. A 2020 review in Neurogastroenterology and Motility confirmed that prolonged colonic transit time is directly correlated with decreased stool water content and increased stool hardness. So you are not just going less often. What you do pass is harder and more difficult to evacuate.
âšī¸Many GLP-1 users report that they "just forget to eat" or find that their portions have decreased dramatically. This appetite suppression is the medication working as intended, but it also removes the dietary bulk that your colon depends on. Constipation management on GLP-1s often requires intentionally adding back fiber and fluid, even when you are eating less overall.
How Common Is Constipation on Ozempic, Wegovy, Mounjaro, and Zepbound?
The clinical trial data gives a reasonable baseline. In STEP 1 (semaglutide 2.4 mg for weight management), constipation was reported in 24.2% of the treatment group compared to 10.1% on placebo. In SUSTAIN 6 (semaglutide for type 2 diabetes at lower doses of 0.5 and 1.0 mg), rates were lower, at 3.2-5.0%. In SURMOUNT-1 (tirzepatide for obesity), constipation affected 16.8-17.1% across the 5 mg, 10 mg, and 15 mg doses.
A few things to note about these numbers. First, the constipation rate in the placebo group of STEP 1 was 10.1%, which tells you that a meaningful percentage of people in any weight management study will report constipation regardless of medication, often due to dietary changes alone. Second, the semaglutide constipation rate was higher at the 2.4 mg obesity dose than at the 0.5-1.0 mg diabetes doses, consistent with the dose-dependent pattern seen across all GI side effects. Third, tirzepatide's constipation rates were slightly lower than semaglutide's weight-management doses, though cross-trial comparison has obvious limitations.
Real-world surveys and post-marketing data suggest rates may be higher outside of clinical trial settings. A 2024 analysis of FDA Adverse Event Reporting System (FAERS) data found that constipation was the second most frequently reported GI complaint for semaglutide after nausea.
What Actually Works for Constipation on GLP-1 Medications?
Management follows a stepwise approach. Start with the least invasive interventions and escalate only as needed. Most patients will find adequate relief in the first two tiers.
Step 1: Fiber and Hydration
Psyllium husk (brand name Metamucil, among others) is the best-studied fiber supplement for functional constipation. It is a soluble, gel-forming fiber that increases stool bulk and water retention. A 2019 systematic review in the American Journal of Gastroenterology confirmed that psyllium improved stool frequency and consistency in patients with chronic constipation, with a number needed to treat (NNT) of 3.
Start with a low dose (one teaspoon, roughly 3.5 g, once daily) and increase gradually over 1-2 weeks to 2-3 servings daily. Starting too high can cause gas and bloating, particularly in a gut that is already moving slowly. Always take psyllium with a full glass of water (at least 8 oz).
Hydration matters independently. When colonic transit is slow, the colon extracts more water from stool. If you are not replacing that water through adequate fluid intake, fiber alone may not be enough. The general recommendation is at least 64 oz (approximately 2 liters) of water daily, though individual needs vary with body size, activity level, and climate. If you are drinking substantially less than this, increasing water intake alone can sometimes resolve mild constipation.
đĄA practical approach: one glass of water with psyllium before breakfast, one glass with lunch, one glass with dinner, and sip throughout the day. Tying hydration to existing habits makes it more sustainable than trying to remember to drink on a schedule.
Step 2: Osmotic Laxatives
If fiber and hydration are not producing adequate results after 1-2 weeks of consistent use, osmotic laxatives are the next step. Polyethylene glycol 3350 (PEG 3350, brand name MiraLAX) is the standard recommendation. It works by holding water in the stool through osmosis, which softens the stool and increases its volume, stimulating peristalsis.
PEG 3350 is well-studied, has a strong safety profile for long-term daily use, and does not cause dependence. A 2016 Cochrane review of osmotic laxatives for chronic constipation concluded that PEG was more effective than lactulose for stool frequency and consistency, with fewer reports of side effects. The standard dose is 17 g (one capful) dissolved in 8 oz of liquid, taken once daily. It can be adjusted up or down based on response.
Magnesium-based options are another consideration. Magnesium citrate and magnesium oxide both have osmotic effects in the colon. Magnesium citrate at 200-400 mg daily is commonly used. It has the additional benefit of addressing the magnesium deficiency that can develop with reduced dietary intake on GLP-1 medications. However, doses above 400 mg can cause loose stools or diarrhea, and patients with kidney disease should use magnesium cautiously.
Step 3: Stimulant Laxatives (Short-Term Only)
Stimulant laxatives like senna (Senokot) and bisacodyl (Dulcolax) directly stimulate colonic contractions. They work and they work quickly, usually within 6-12 hours. However, they are not designed for daily long-term use. Chronic use can lead to tolerance (needing higher doses for the same effect), electrolyte disturbances, and potentially melanosis coli (a harmless but visible darkening of the colonic lining).
These are best reserved for occasional use when osmotic laxatives and fiber have not produced a bowel movement in 3 or more days. If you find yourself needing stimulant laxatives more than twice a week, that is a signal to escalate your management plan, not to increase the stimulant dose.
Step 4: Prescription Options and Prokinetics
For refractory constipation that does not respond to the above measures, several prescription options exist. Lubiprostone (Amitiza) is a chloride channel activator that increases fluid secretion in the small intestine. Linaclotide (Linzess) and plecanatide (Trulance) are guanylate cyclase-C agonists that similarly increase intestinal fluid secretion and accelerate transit. All three are FDA-approved for chronic idiopathic constipation.
Prokinetic agents, which directly stimulate GI motility, are another avenue. Prucalopride (Motegrity) is a selective 5-HT4 receptor agonist approved for chronic idiopathic constipation. It accelerates colonic transit and has been shown to increase the frequency of complete spontaneous bowel movements. A 2019 meta-analysis in Alimentary Pharmacology and Therapeutics found that prucalopride significantly improved bowel function in patients with chronic constipation refractory to standard laxatives.
Whether prokinetics interact with GLP-1 receptor agonists at a pharmacological level is not well studied. They work through different receptor systems (5-HT4 vs. GLP-1R), so additive effects on motility are theoretically possible. Some gastroenterologists are using prucalopride alongside GLP-1 medications in clinical practice, but this is based on clinical judgment rather than trial data specific to this combination.
Does Physical Activity Help with GLP-1 Constipation?
Yes, and the evidence for this is reasonably good, though not specific to GLP-1 users. A 2019 systematic review in the Scandinavian Journal of Gastroenterology found that regular physical activity (particularly aerobic exercise) was associated with improved colonic transit time and stool frequency. The mechanisms likely involve increased abdominal muscle activity, enhanced vagal tone, and direct stimulation of colonic motility through the gastrocolic reflex.
Walking is the simplest intervention. A 10-15 minute walk after meals can stimulate the gastrocolic reflex, the coordinated increase in colonic motility that normally follows eating. This reflex may be blunted on GLP-1 medications due to slower gastric emptying, but mechanical activity (walking, moving) can partially compensate.
What Helps You Track What Is Working?
Constipation management is iterative. What works at one dose may not be sufficient after an escalation. Keeping a simple log of bowel frequency, stool consistency (the Bristol Stool Scale is a useful reference), fluid intake, fiber intake, and any laxative use helps you and your prescriber identify patterns and adjust the plan. Tools like GLP1Gut can help you track these variables alongside your GLP-1 dose changes, so you can see whether your constipation correlates with specific doses, dietary shifts, or hydration lapses.
When Is Constipation on a GLP-1 a Sign of Something More Serious?
Most GLP-1-related constipation is functional and manageable. But there are red flags that warrant medical evaluation.
- No bowel movement for 7 or more days despite active management with fiber, hydration, and osmotic laxatives.
- Severe abdominal pain or distension, particularly if it is progressive rather than intermittent.
- Nausea and vomiting in combination with constipation, which may indicate gastroparesis or ileus.
- Rectal bleeding, which should never be attributed to constipation alone without evaluation.
- Significant worsening of constipation that started mild but has become severe over weeks to months, which may indicate the development of intestinal methanogen overgrowth (IMO) or other secondary causes.
Gastroparesis (severely delayed gastric emptying beyond the expected pharmacological effect) is a recognized, though uncommon, adverse outcome of GLP-1 therapy. The FDA updated prescribing information for semaglutide in 2023 to include more prominent mention of gastroparesis-like symptoms. If constipation is accompanied by severe early satiety, recurrent vomiting of undigested food, and significant abdominal distension, your prescriber may recommend a gastric emptying study.
â ī¸If you have not had a bowel movement in a week and are experiencing abdominal pain and vomiting, do not wait for your next scheduled appointment. This combination can indicate bowel obstruction, which is a medical emergency. Go to urgent care or the emergency department.
Should You Lower Your GLP-1 Dose Because of Constipation?
This is a reasonable question and one worth discussing with your prescriber. In some cases, temporarily holding at a lower dose for an additional 4-8 weeks while optimizing constipation management can allow the GI tract to adapt before the next escalation. The Wegovy prescribing information specifically notes that dose escalation can be delayed if GI side effects are not tolerable.
Stopping the medication entirely because of constipation is rarely necessary and is generally not recommended unless all management strategies have failed and the constipation is significantly affecting quality of life. The metabolic and weight-management benefits of GLP-1 medications are substantial, and constipation is almost always manageable with the stepwise approach described above.
If you do stop a GLP-1 medication, be aware that constipation may temporarily worsen before it improves. The GI tract has adapted to a certain level of motility suppression, and the rebound period can be unpredictable. This is discussed in more detail in our article on coming off GLP-1 medications and digestive rebound.
Frequently Asked Questions
Can I take MiraLAX every day while on Ozempic?
Yes. Polyethylene glycol 3350 (MiraLAX) is safe for daily long-term use. A 2016 Cochrane review confirmed its safety and efficacy for chronic constipation. It does not cause dependence and does not interact with semaglutide or tirzepatide. Adjust the dose based on your response: some people need half a capful, others need a full dose.
Is magnesium or MiraLAX better for GLP-1 constipation?
Both are effective. MiraLAX has more robust clinical trial data for chronic constipation. Magnesium citrate (200-400 mg daily) has the added benefit of supplementing a mineral that may be low due to reduced food intake on GLP-1s. Some patients use both. Avoid high-dose magnesium if you have kidney disease.
Will constipation go away on its own after I adjust to my GLP-1 dose?
Sometimes, but less reliably than nausea. Nausea typically resolves within 4-8 weeks at a stable dose due to receptor desensitization. Constipation is driven partly by ongoing reduced food intake and is more likely to persist. Active management (fiber, hydration, osmotic laxatives) is usually needed throughout treatment.